Image

Global Chronic Ocular Surface Pain Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • May 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • May 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Chronic Ocular Surface Pain Market, By Drug Class (Antibiotics, Nonsteroidal Anti-Inflammatory (NSAID), Corticosteroids, Others), Application (Sinusitis, Migraines, Glaucoma, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029

Chronic Ocular Surface Pain Market

Market Analysis and Size

In recent years, the chronic ocular surface pain market is anticipated to grow rapidly during the forecast period. Eye pain can manifest itself in a variety of ways, from a strong pain in the eye to minor discomfort or itching. Because the symptoms of eye pain range from simple refractive errors to potentially sight-threatening disorders like glaucoma and uveitis, the origin of these aches can be anything from simple refractive errors to potentially sight-threatening disorders like glaucoma and uveitis. An issue in the eye itself might induce a feeling of discomfort or pain in the eye. It can also be caused by a problem with any of the structures around the eye, as well as referred pain from tissues that have similar innervation to the ocular tissues. Primary care physicians, neurologists, and ophthalmologists regularly see patients with eye pain or periorbital pain.

Data Bridge Market Research analyses that the chronic ocular surface pain market was valued at USD 289 million in 2021 and is expected to reach USD 450.30 million by 2029, registering a CAGR of 5.70% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Chronic ocular surface pain is also known as ophthalmalgia, which is categorized by generalized pain in the eyes that is persistent, intense, and pressing. Medical diseases that induce inflammation of the ocular surface, including as conjunctivitis, glaucoma, and migraine, are the most common causes.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Drug Class (Antibiotics, Nonsteroidal Anti-Inflammatory (NSAID), Corticosteroids, Others), Application (Sinusitis, Migraines, Glaucoma, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Zydus Cadila (India), AstraZeneca (UK), Johnson & Johnson (US), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), LEO Pharma A/S (Denmark), Glenmark Pharmaceuticals Limited (India), Aurobindo Pharma (India), Lupin (India), Reata Pharmaceuticals, Inc (US), Kala Pharmaceuticals, Inc (US)

Market Opportunities

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Rising investment for the development of advanced technologies
  • Surging drug approvals and launches

Chronic Ocular Surface Pain Market Dynamics

Drivers

  • Increasing prevalence of bacterial and viral ocular infections

The rising prevalence of bacterial and viral ocular infections is estimated to enhance the market's growth.

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of chronic ocular surface pain market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

  • Growing number of geriatric population

The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to get chronic ocular surface pain, further estimated to enhance the market’s growth rate.

  • Increasing prevalence of dry eyes among people

The rising prevalence of dry eyes among people is anticipated to propel the market's growth rate. Thyroid disorders, lupus, Sjogren’s syndrome, diabetes, rheumatoid arthritis, scleroderma, and others are the various diseases contributing to the high prevalence of dry eyes among people.    

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the chronic ocular surface pain market. Additionally, increasing demand for standard treatment and sedentary lifestyle of people will result in the expansion of chronic ocular surface pain market.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the chronic ocular surface pain market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate. 

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the chronic ocular surface pain market growth during the forecast period.

Restraints/Challenges

On the other hand, high cost high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the chronic ocular surface pain market. Additionally, strict regulatory policies and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This chronic ocular surface pain market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the chronic ocular surface pain market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Chronic ocular surface pain market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Chronic Ocular Surface Pain Market

Over the projected period, the chronic ocular surface pain market was expected to be constrained by the COVID-19 outbreak. Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in a number of nations had imposed nationwide lockdowns in order to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The chronic ocular surface pain market was hampered by the supply chain slowness.

Global Chronic Ocular Surface Pain Market Scope

The chronic ocular surface pain market is segmented on the basis of drug class, application, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

  • Antibiotics
  • Nonsteroidal Anti-Inflammatory (NSAID)
  • Corticosteroids
  • Others

Application

End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Chronic Ocular Surface Pain Market Regional Analysis/Insights

The chronic ocular surface pain market is analysed and market size insights and trends are provided by country, drug class, application, end-users and distribution channel as referenced above.

The countries covered in the chronic ocular surface pain market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the chronic ocular surface pain market because of the rising prevalence of ocular diseases in this region. Additionally, rising healthcare expenditure and technological advancement in diagnostic procedure will further propel the market’s growth rate in this region.

Asia-Pacific are expected to grow during the forecast period of 2022 to 2029  due to presence of major generic manufacturers in this region. Also, development of healthcare infrastructure and rising geriatric population will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Chronic Ocular Surface Pain Market Share Analysis

The Chronic ocular surface pain market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to chronic ocular surface pain market.

Some of the major players operating in the chronic ocular surface pain market are:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (US)
  • Teva Pharmaceutical Industries Ltd.(Israel)
  • Sanofi (France)
  • Pfizer Inc. (US)
  • GlaxoSmithKline plc (UK)
  • Novartis AG (Switzerland)
  • Zydus Cadila (India)
  • AstraZeneca (UK)
  • Johnson & Johnson (US)
  • Bayer AG (Germany)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Bristol-Myers Squibb Company (US)
  • Eli Lilly and Company (US)
  • LEO Pharma A/S (Denmark)
  • Glenmark Pharmaceuticals Limited (India)
  • Aurobindo Pharma (India)
  • Lupin (India)
  • Reata Pharmaceuticals, Inc (US)
  • Kala Pharmaceuticals, Inc (US)


SKU-
Why Choose Us


Frequently Asked Questions

The market value for the Chronic Ocular Surface Pain Market is expected USD 450.30 million by 2029.
The Chronic Ocular Surface Pain Market is to grow at a CAGR of 5.70% during the forecast period of 2022 to 2029
On the basis of application, the Chronic Ocular Surface Pain Market is segmented into Sinusitis, Migraines, Glaucoma, Others.
The major players operating in the Chronic Ocular Surface Pain Market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Zydus Cadila (India), AstraZeneca (UK), Johnson & Johnson (US), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), LEO Pharma A/S (Denmark), Glenmark Pharmaceuticals Limited (India), Aurobindo Pharma (India), Lupin (India), Reata Pharmaceuticals, Inc (US), Kala Pharmaceuticals, Inc (US).